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Abstract
Objective: To evaluate evidence on the association between CYP2D6 genotype and tamoxifen response through.
Design: Systematic review and meta-analysis of prospective, cross-sectional and case-control studies published to
2012. For each study, relative risks and 95% confidence intervals were extracted and pooled with a fixed and random
effects model. Heterogeneity, publication bias, subgroup, and meta-regression analyses were performed.
Data Sources: PubMed (inception-2012) and EMBASE (inception-2012).
Eligibility Criteria for Selecting Studies: Criteria for inclusion were studies reporting breast cancer outcomes in
patients treated with tamoxifen and genotyped for polymorphisms in the CYP2D6 gene.
Results: Twenty-five studies of 13,629 individuals were identified, of which 22 investigated the association of
CYP2D6 genotype with outcomes in breast cancer women all receiving tamoxifen treatment (“treatment-only”
design). Three randomized trials evaluated the effect of CYP2D6 genotype on tamoxifen response (“effect
modification” design). In analysis of treatment-only studies, the relative risk (RR) of all-cause mortality (>307 events
in 4,936 patients) for carriers of a CYP2D6 reduced function allele was 1.11 (95% confidence interval (CI): 0.94 to
1.31) compared to individuals with normal/increased function CYP2D6 alleles. When we investigated a composite
outcome including all-cause mortality and surrogate endpoints for overall survival (>307 events in 6,721 patients),
carriers of a CYP2D6 reduced function allele had a RR of 1.27 (95% CI: 1.11 to 1.45). From two randomized trials
that permitted effect-modification analysis, one had only 154 patients and showed evidence of effect modification of
tamoxifen by CYP2D6 genotype for distant recurrence but was directionally opposite to that predicted, whereas a
larger trial of 2,537 patients failed to show evidence of effect modification for breast cancer-free interval (P values for
interaction 0.02 and 0.44, respectively).
Conclusions: Based on these findings, there is insufficient evidence to recommend CYP2D6 genotyping to guide
tamoxifen treatment.
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Introduction
Breast cancer is one of the leading causes of cancer-related
mortality in women [1,2]. Tamoxifen, a selective estrogen
receptor modulator, was first approved by the U.S. Food and
Drug Administration (FDA) in 1977 for the treatment of
metastatic breast cancer [3], and has also been approved for
primary prevention in women at high risk of breast cancer, for
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adjuvant treatment (given after primary treatment), and for
ductal carcinoma in situ [4].
A meta-analysis of 20 randomized clinical trials (RCTs)
including 10,645 women with estrogen receptor positive breast
cancer demonstrated that, compared to no tamoxifen, adjuvant
tamoxifen reduced breast cancer recurrence (relative risk (RR)
0.53, 95% CI: 0.47 to 0.59) and breast cancer mortality (RR
0.71, 95% CI: 0.61 to 0.81) at 5 years [5]. Furthermore, the
benefit of tamoxifen persisted if treatment was continued for 10
years after its initiation [6].
Tamoxifen itself is only a weak modulator of the estrogen
receptor while its metabolites (including endoxifen) are thought
to be many times more potent [7]. Several enzymes are
involved in tamoxifen metabolism (Figure S1) [8], and recent
attention has focused on the hepatic cytochrome P450 2D6
(CYP2D6), with interest that genetic variants in CYP2D6 that
alter the level or activity of the encoded enzyme might alter the
response to tamoxifen [9]. A U.S. Food and Drug
Administration (FDA) Clinical Pharmacology Subcommittee
convened in 2006 and agreed that “the scientific evidence on
the metabolism of tamoxifen demonstrates CYP2D6 is an
important pathway in the formation of endoxifen” and
recommended the drug label be updated to reflect this [10].
We investigated the evidence of the association between
CYP2D6 genotype and response to tamoxifen treatment in
individuals with breast cancer by conducting a systematic
review and meta-analysis.
Methods
To be eligible for inclusion, studies reported breast cancer
outcomes in relation to CYP2D6 genotype in humans of any
ethnic group.
Search strategy
Following PRISMA guidance [11], we searched PubMed and
EMBASE from inception to 29th January 2012. The search
terms included the generic and proprietary drug names
(including Novaldex, Zitazonium, Soltamox and Tomaxithen)
and the gene name (CYP2D6, NCBI Entrez Gene 1565, and
less specific search terms such as Cytochrome P450). Full
details of the search string are provided in the Supplementary
Methods reported in Text S1. We limited the search to studies
that reported the association between CYP2D6 genotype and
tamoxifen response in humans. Eligible studies had an abstract
containing the keywords “tamoxifen” and “CYP2D6” and
reported original data. Editorials and reviews were omitted. The
search was complemented by hand-searches of the
bibliographies of included articles and of narrative reviews.
The search was conducted by DWKL and a random subset
of studies was double-checked by MVH and ADH.
Uncertainties were resolved by consensus. When questions
remained, corresponding authors were contacted. The
literature search was not restricted by ethnicity or language.
Grouping of CYP2D6 alleles
We used information from The Human Cytochrome P450
(CYP450) Allele Nomenclature Database (http://
www.cypalleles.ki.se, Accessed 2013 Sep 4) and the
Pharmacogenetics Knowledgebase (http://www.pharmgkb.org,
Accessed 2013 Sep 4) to classify CYP2D6 genotypes. For the
main analysis, we compared individuals with any reduced/non-
functional CYP2D6 allele to individuals with normal/increased
function alleles. In studies that reported individual CYP2D6
genotype comparisons (e.g. *4 vs. *1), individuals carrying one
or more reduced functional alleles (i.e. *9, *10, *17, *29, *36
and *41 alleles) and/or non-functional alleles (i.e. *3, *4, *5, *6,
*7, *8, *11, *12, *13, *14, *15, *16, *19, *20, *21, *38, *40 and
*42 alleles) were grouped together and compared with
individuals carrying normal/increased function CYP2D6 alleles
(i.e. *1, *2, *33 and *35 alleles). For studies that grouped
CYP2D6 alleles into so-called “predicted phenotypes”, the poor
metabolizers and intermediate metabolizers were grouped (as
these approximate to carriage of one or more reduced
functional alleles) and were compared with extensive
metabolizers and ultra metabolizers (please see Table S1 for
further details). We expected individuals carrying the reduced
function CYP2D6 alleles to have higher risk of breast cancer
outcomes (on the basis that less tamoxifen would be
metabolized to the active metabolites in these individuals)
compared to individuals that did not harbour these alleles.
In addition to the main genetic classification, we investigated
a dose-response relationship by studying individuals with one
copy vs. two copies of any reduced/non-functional CYP2D6
allele compared to the normal/increased function alleles
(please see Text S1 for full details).
Outcomes analysed in the meta-analysis
For the treatment-only studies (in which all individuals were
exposed to tamoxifen), we synthesized a hierarchy to reflect
clinical importance of the reported study outcomes based on
recent narrative reviews of clinical trials in cancer [12–15]. We
had three main outcomes of interest. First, our primary
outcome was specific to mortality and termed “all-cause
mortality”, which included breast cancer specific mortality,
overall survival and all-cause mortality. Second, we included
surrogate endpoints for overall survival such as progression
free survival (PFS), which included non-fatal events. Thus, this
secondary outcome was a composite of all-cause mortality and
surrogate endpoints for overall survival. Third, to maximise the
number of studies that could be incorporated into the analysis,
we added outcomes that consisted of non-fatal events (such as
any recurrence, metastases, breast cancer free interval) to the
composite. This third outcome therefore consisted of a
composite of all-cause mortality, surrogate endpoints for overall
survival (including non-fatal events), and non-fatal events. For
each of these three main outcomes, we used a hierarchy such
that if a study reported fatal and non-fatal events separately,
only the fatal events from this study would contribute towards
each of the three composites. Further details of the three
composite outcomes and the contribution of individual studies
to each outcome are provided in Figure S2 and Table S2.
In addition to the main outcomes, we conducted separate
meta-analyses for the following individual outcomes for the
treatment-only analysis: (i) breast cancer-specific mortality; (ii)
overall survival/all-cause mortality; (iii) surrogate endpoints for
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overall survival (including non-fatal events); (iv) non-fatal
events (breast cancer recurrence), and; (v) the adverse drug
reaction, hot flushes.
For the effect modification studies, we used outcomes
reported in the clinical trials.
We extracted counts of events by genotype and used these
to generate odds ratios for each study. When event counts
were not available, we used the reported univariate effect
estimates. When neither event counts nor univariate estimates
were reported, we used the reported multivariate effect
estimates. When a study reported both single CYP2D6
genotype (e.g. *4 vs. *1) and grouped CYP2D6 genotypes
comparisons (e.g. poor metabolizers vs. extensive
metabolizers), the latter was used as it incorporated more
genetic variation in CYP2D6.
Statistical analysis
The analysis was split into two main types depending on the
design [16]: the treatment-only meta-analysis was limited to
studies of individuals all receiving tamoxifen, and the effect-
modification analysis was based on an evaluation of
heterogeneity in the tamoxifen treatment effect size in groups
of differing genotypes studied within randomised controlled
trials.
For the treatment-only analysis, we used fixed and random
effects meta-analysis models to pool estimates from individual
studies. Unless otherwise stated, meta-analyses used the fixed
effects model [17]. The summary relative risk (RR,
incorporating odds ratio, hazards ratio and rate ratio) was used
to describe the pooled summary estimates derived from meta-
analyses. Heterogeneity between studies was quantified using
the I2 statistic and tested using Cochrane’s Q test [17].
For the effect-modification analysis, we used the Bland and
Altman method [18] to test for evidence of heterogeneity
between subgroups of the clinical trials, grouped according to
CYP2D6 genotype.
We used several techniques to investigate potential sources
of bias. Publication bias was investigated by visual inspection
of the funnel plot and quantified by the intercept from linear
regression [19]. The stability of each summary effect estimate
was evaluated using an influence analysis that investigated the
effects of removing each individual study from the meta-
analysis on the overall meta-analysis summary. We conducted
subgroup analyses of the composite all-cause mortality and
surrogate endpoints for overall survival outcome to investigate
if the association differed by study design, patient
characteristics, treatment and genotyping method (see Text S1
for full details). We used this outcome for subgroup analyses
as the sample size was larger. Finally, we investigated risk of
bias in the randomized trials used for effect modification
analysis using criteria from the Cochrane Handbook for clinical
trials [17].
We investigated the potential for a dose-response
relationship on the treatment-only analysis by conducting meta-
regression analyses, testing a linear relationship between the
number of CYP2D6 reduced function alleles and the risk of
each composite outcome.
All statistical analyses were performed using Stata v11.2
(StataCorp, College Station, Texas, USA) and reported P-
values are two-sided. For the treatment-only analysis, a P-
value <0.05 was used to indicate evidence against the null
hypothesis of no association. In the subgroup analysis of
treatment-only studies (see Text S1), we adjusted the P-value
(using the Bonferroni method) to take into account multiple
testing, thus our threshold for nominal significance on subgroup
analysis was P<0.002 (calculated from 0.05/23).
Results
Study inclusion
We identified 25 studies including 13,629 participants that
fulfilled our selection criteria (Figure S3). The characteristics of
the 25 studies are presented in Table 1 and Tables S3-S5.
All identified studies were conducted in women. The median
age was 58 years (range 41 to 76) and median sample size per
study was 462 participants (range 84 to 3155). In the 17 of 25
(68%) studies that reported duration of follow-up, the median
duration was 6.3 years (range 4.5 to 11.4). Most studies (16 of
22 that reported ethnicity) reported data principally on
Caucasian individuals. The breast cancer stage of study
participants ranged from 0 to IV (details reported in Table 1).
Twenty-four of 25 (96%) studies reported information on
hormone receptor status, with the majority of studies (17 of 24,
71%) evaluating a mixture of ER+ and ER- breast cancers.
Only six of 25 (24%) studies reported that genotype
ascertainment was conducted with blinding to clinical
outcomes, and only three studies (12%) reported that clinical
outcomes were ascertained with blinding to CYP2D6 genotype
(Table S3).
There were 21 unique outcomes reported across the 25
studies (Figure S4), which we grouped into three composite
outcomes (Figure S2).
Thirty-six CYP2D6 star (*) alleles were genotyped across the
studies, with only four alleles (*4, *5, *6, *41) genotyped in half
or more of the 13,629 individuals across the 25 studies. The
most commonly genotyped CYP2D6 alleles were *4 in 23
studies (genotyped in 96% of participants), followed by *41 in
13 studies (genotyped in 77% of participants). There were
several * alleles that were genotyped but not reported (Figure
S5).
Treatment-only meta-analysis of composite outcomes
All-cause mortality.  Six studies (>307 events in 4,936
participants) reported data that could be incorporated into the
all-cause mortality analysis. Compared to those with normal or
increased function alleles, individuals with any copy of a
reduced function CYP2D6 allele had a RR of death of 1.11
(95% CI: 0.94 to 1.31; I2=20%) in the fixed effects analysis and
1.12 (95% CI: 0.90 to 1.41) in random effects meta-analysis
(Figure 1, Table S6 and Figure S6).
All-cause mortality and surrogate endpoints for overall
survival.  When we studied a composite encompassing all-
cause mortality as well as surrogate endpoints for overall
survival, a total of 10 studies (>307 events in 6,721
participants) could be incorporated into the analysis. Individuals
CYP2D6 Genotype and Tamoxifen Response
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Table 1. Characteristics of the 25 studies identified by the systematic review.
First author, reference,
year
Study
design
Total
partici-
pants
Duration of
follow-up
(years) Ethnicity Age (years)
Breast cancer
stage
Estrogen receptor
(ER) status
Progest-erone
receptor (PR)
status
Outcomes
reported
Abraham et al. [37],
2010 Cohort 3155 NR
Caucasian
(98.8%) 53
I, II, III, IV or
unknown
ER+, ER- or
unknown NR
BCSS, OS/all-
cause mortality
Bijl et al. [38], 2009 Cohort 85 NR Caucasian 75.5 NR NR NR
Breast cancer
mortality, Cancer
mortality, All-cause
mortality
Goetz et al. [39], 2005 Cohort 223 11.4 Caucasian(92%) 68 NR ER+ NR
OS, DFS, RFT, Hot
flush
Gonzalez et al. [40],
2007 Cohort 84  5.5 NR  51.5 I, II or III ER+ or ER- PR+ or PR-
Disease
recurrence/ relapse
Kiyotani et al. [41], 2011 Cohort 462 6.8 Asian  51 NR ER+, ER- orunknown
PR+, PR- or
unknown RecFS
Lammers et al. [42],
2010 Cohort 99 NR
Caucasian
(95.1%), Asian
(3.9%), African
(1%)
51.8 NR ER+ PR+ OS, TTP
Lash et al. [43], 2011 Case-Control 1682 NR Caucasian NR I, II or III
ER+, ER- or
unknown NR
Breast cancer
recurrence
Madlensky et al. [44],
2009 Cohort 1411 NR NR NR I or II ER+ NR Hot flush
Morrow et al. [45], 2011 Case-Control 106 9 NR 58 0/I, II or III ER+ or ER- PR+ or PR- Disease recurrence
Newman et al. [46],
2008 Cohort 205 NR
Caucasian
(7.8%
Ashkenazi
Jewish)
43 NR ER+ or ER- NR OS, RecFS, TTRec
Nowell et al. [47], 2005 Cohort 337 5.4
Caucasian
(81%),
African–
American
(19%).
NR I, II, III or IV ER+ or ER- PR+ or PR- OS, PFS
Okishiro et al. [48], 2009 Cohort 173 4.9 Asian 47 NR ER+ or ER- PR+ or PR- RecFS
Park et al. [49], 2011 Cohort 110 6.2 Asian 43.6 NR ER+, ER- orunknown
PR+, PR- or
unknown RecFS, OS
Park et al. [50], 2011 Cohort 716 5.6 Asian  45 I, II, or III ER+, ER- orunknown
PR+, PR- or
unknown RecFS
Rae et al. [20], 2012 RCT 1203 10 Caucasian NR I, II, or IIIA ER+, ER- orunknown
PR+, PR- or
unknown
Distant recurrence
rate, Any
recurrence rate
Regan et al. [22], 2012 RCT 2193 6 Caucasian(98%)  61 NR ER+ or ER- PR+ BCFI, Hot flush
Schroth et al. [51], 2007 Cohort 486 5.9 Caucasian 60 NR ER+ or ER- NR OS, EFS, RFT,Relapse risk
Schroth et al. [52], 2009 Cohort 1325 6.3 Caucasian 66 I, II or III ER+, ER- orunknown
PR+, PR- or
unknown
OS, DFS, EFS,
TTRec
Stingl et al. [53], 2010 Cohort 493 7 Caucasian 59 NR ER+ NR
Disease related
event recurrence,
TTP, PFS
Teh et al. [54], 2011 Cohort 95 NR Asian 51 0-II or III&IV ER+ or ER- PR+ or PR- Recurrence &metastasis risk
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with any copy of a reduced function CYP2D6 allele had a RR of
achieving the composite of 1.27 (95% CI: 1.11 to 1.45; I2=56%)
for fixed effects and 1.34 (95% CI: 1.06 to 1.69) for random
effects meta-analysis compared to individuals with normal/
increased function CYP2D6 alleles (Figure 1, Table S6 and
Figure S7).
All-cause mortality, surrogate endpoints for overall
survival and non-fatal outcomes.  When our composite
included all-cause mortality, surrogate endpoints for overall
survival as well as non-fatal breast cancer events (17 studies,
>1,088 events in 9,555 participants), individuals with any copy
of a reduced function CYP2D6 allele had a RR of achieving this
end point of 1.19 (95% CI: 1.07 to 1.33; I2=53%) for fixed
effects and 1.22 (95% CI: 1.01 to 1.46) for random effects
meta-analysis compared to those with normal or increased
function CYP2D6 alleles (Figure 1, Table S6 and Figure S8).
Treatment-only meta-analysis of individual outcomes
In the treatment only analysis of individual outcomes, the risk
for breast cancer-specific mortality (>35 events in 2 studies
with 3,240 individuals) was RR 1.12; 95% CI: 0.89 to 1.40 and
for overall survival/all-cause mortality (>272 events in 6 studies
with 5,057 individuals) it was RR 1.11; 95% CI: 0.95 to 1.29)
(Figure 2 and Table S6). Carriage of any copy of a reduced
function CYP2D6 allele was associated with meeting a
surrogate endpoint for overall survival (>385 events in 6 studies
with 3,270 individuals; RR 1.43; 95% CI: 1.22 to 1.68) as well
as non-fatal recurrence (>989 events in 11 studies with 5,445
individuals; RR 1.34; 95% CI: 1.17 to 1.54) (Figure 2 and Table
S6).
Subgroup analyses
We conducted subgroup analysis for the composite that
included all-cause mortality together with surrogate endpoints
for overall survival (including non-fatal events). Although there
was a suggestion of a differential association of CYP2D6
genotype according to patient ethnicity, concomitant therapy,
breast cancer stage/grade and menopause status, none of the
subgroup analyses surpassed our a priori Bonferroni-adjusted
P-value threshold of <0.002 (Figure 3 and Figure S9).
Publication bias and stability of effect estimate
The funnel plots for the three composite outcomes appeared
symmetrical (Figure S10), supported by the lack of evidence on
formal statistical testing (Harbord test P-values all >0.05). We
did not identify evidence of excessive influence by any
individual study for each of the three composite outcomes
(Figure S11).
Gene dose-response relationship
When we investigated the potential for a gene dose-
response relationship between the number of reduced function
CYP2D6 alleles and composites outcomes in patients treated
with tamoxifen, the point estimate for two reduced function
CYP2D6 alleles was consistently of greater magnitude than for
one copy in each of the three composite outcomes, however
the 95% CI were wide and there was no evidence for a trend
on formal statistical testing (all P values >0.05) (Figure 1).
Effect-modification analysis
Of 25 potentially eligible studies, three were trials with
participants randomized to tamoxifen or a comparator group
(Table 1). One of the trials [20] did not report information in a
Table 1 (continued).
First author, reference,
year
Study
design
Total
partici-
pants
Duration of
follow-up
(years) Ethnicity Age (years)
Breast cancer
stage
Estrogen receptor
(ER) status
Progest-erone
receptor (PR)
status
Outcomes
reported
Thompson et al. [55],
2010 Cohort 618
4.9 (Cohort
1), 9.4
(Cohort 2)
Caucasian
60.5
(Cohort 1),
63.1
(Cohort 2)
I, II or III ER+ NR RFS
van Schaik et al. [56],
2011 Cohort 742 NR
Caucasian
(>95%) 59 NR ER+
PR+, PR- or
unknown TTF
Wegman et al. [21],
2005 RCT 226 10.7 Caucasian NR NR ER+ or ER- NR
Distant recurrence
rate, Distant RFS
Wegman et al. [57],
2007 Cohort 677 7.1 Caucasian 69 II or III ER+ NR RecFS
Xu et al. [58], 2008 Cohort 293 5.3 Asian NR 0, I, II, III orunknown
ER+, ER- or
unknown
PR+, PR- or
unknown DSS, DFS
Footnotes: BCFI: breast cancer-free interval, BCSS: breast cancer-specific survival, Cohort 1: Dundee, UK, Cohort 2: Manchester, UK, DFS: disease-free survival, DSS:
disease-specific survival, EFS: event-free survival, ER- estrogen receptor negative, ER+: estrogen receptor positive, HR: hazard ratio, NA: not applicable, NR: not recorded,
OR: odds ratio, OS: overall survival, PFS: progression-free survival, PR- progesterone receptor negative, PR+: progesterone receptor positive, RCT: randomized-controlled
trial, RFS: relapse-free survival, RFT: relapse-free time, RecFS: recurrence-free survival, TAM- tamoxifen non-treated group, TAM+: tamoxifen-treated group, TTF: time to-
treatment failure, TTP: time to progression, TTRec: Time to recurrence. Age represents mean age at diagnosis, first tamoxifen use or surgery.
doi: 10.1371/journal.pone.0076648.t001
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way that permitted analysis of heterogeneity of treatment effect
by genotype category. Of the two remaining trials, the risk of
bias for one trial was high, and for the other it was low (Table
S7).
In the trial reported by Wegman et al. [21] of 154 patients (in
which the risk of bias was high, Table S7), the OR of distant
recurrence for individuals with any copy of the CYP2D6*4
reduced function allele was 0.18 (95% CI: 0.05 to 0.61) for
tamoxifen compared to no tamoxifen, whereas for individuals
with the normal CYP2D6 allele (*1/*1), the corresponding OR
was 0.96 (95% CI: 0.45 to 2.04). A test for interaction yielded
evidence for effect modification (P=0.02) (Table 2). However,
the point estimate for the CYP2D6*4 allele was directionally
opposite to that expected according to the predicted phenotypic
consequence of the genetic variant.
In the trial reported by Regan et al. [22] including 2,537
participants randomized to tamoxifen or the aromatase inhibitor
letrozole, two outcomes were analysed: (i) breast cancer-free
interval (defined from recruitment to the first breast cancer
event [local, regional, or distant recurrence] or a new invasive
contralateral breast cancer) and (ii) hot flushes. The OR for
breast cancer-free interval for tamoxifen compared to letrozole
in individuals with any reduced function CYP2D6 allele was
1.05 (95% CI: 0.72 to 1.52), and for individuals with normal
function CYP2D6 allele, it was 1.26 (95% CI: 0.94 to 1.69), with
no evidence for effect modification (P=0.44) (Table 2). There
was also no evidence for an interaction between CYP2D6
genotype and tamoxifen therapy for the adverse outcome of
hot flush (P=0.52) (Table 2).
It was not possible to provide a pooled summary estimate for
the effect of tamoxifen versus comparator group stratified by
CYP2D6 genotype, as the comparator groups used and the
outcomes reported were different in the two trials.
Discussion
We investigated the evidence base on the association
between CYP2D6 genotype and clinical outcomes following
tamoxifen treatment for breast cancer. A total of 25 studies
were identified comprising 13,629 patients with breast cancer
adding to prior meta-analyses [23,24] by including 5 more
studies, providing new insight on a range of outcomes,
Figure 1.  Meta-analysis pooled estimates from treatment-only analysis of the association of any, one or two copies of a
reduced function CYP2D6 allele vs. none with composite breast cancer outcomes.  Footnotes: § P-value represents test for
trend, conducted using metaregression assuming a linear dose-response relationship between number of CYP2D6 alleles and
summary effect estimate.
doi: 10.1371/journal.pone.0076648.g001
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investigating a potential gene dose-response relationship, and
an assessment of data from trials that investigated effect
modification of tamoxifen by CYP2D6 genotype status.
In the treatment-only analysis for all-cause mortality, the
point estimate was consistent in direction with that expected
from the hypothesis that reduced tamoxifen metabolism is
associated with a poorer outcome but the confidence limits
were wide and included the null value (of RR=1). When we
used a less stringent composite outcome encompassing all-
cause mortality and surrogate endpoints for overall survival
(including non-fatal events), individuals carrying any copy of a
reduced function CYP2D6 allele had a higher risk of an
adverse outcome than individuals with normal/increased
function CYP2D6 alleles. In the analysis of the individual
outcomes, we did not identify an association between CYP2D6
genotype and mortality, but did find an association between
CYP2D6 genotype and surrogate endpoints for overall survival
(including non-fatal events). Although it was not possible to
pool information from the treatment trials in the effect-
modification analysis, because of the different comparator
arms, neither trial individually provided support for the
hypothesis that carriage of reduced function CYP2D6 alleles
modified the treatment response to tamoxifen, regardless of
whether the comparator was a placebo or letrozole (a drug that
is not considered to be metabolized by CYP2D6) [25].
However, as is common with many randomized trials, power
may be a real limitation of subgroup analyses [26]. Taken
together, these data provide inconsistent and inconclusive
evidence on the clinical implications of individual variation in
CYP2D6 metaboliser status and the outcome from tamoxifen
treatment.
The association of CYP2D6 genotype with surrogate
endpoints for overall survival (both individually and as part of a
composite) on the treatment-only analysis is worthy of
discussion. Controversy exists on the validity of using
surrogates when evaluating cancer treatments [27]. For
decades, overall survival has been considered the optimal
endpoint of investigation for assessing treatment efficacy in
medical oncology, partly due to the simplicity of case
ascertainment [12]. However, use of overall survival requires a
large sample size and long duration of follow-up, increasing the
cost of trials in which it is the primary outcome. This has fuelled
debate about whether it is possible to use surrogate endpoints
to make inferences regarding a treatment’s efficacy on overall
survival [28–32]. Importantly, the FDA has recently approved
drugs based on these surrogate measures [33]. Criticisms of
Figure 2.  Meta-analysis pooled estimates from treatment-only analysis of the association of any CYP2D6 reduced function
alleles vs. none with individual outcomes.  Footnotes: Non-fatal events included breast cancer outcomes that were not fatal.
doi: 10.1371/journal.pone.0076648.g002
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the use of surrogate endpoints for overall survival are that they
may be prone to investigator bias and sensitive to the time of
assessment, making them potentially unsuitable for cohort
studies and non-blinded randomized trials [34] and that they
may not reflect clinically-meaningful outcomes [14].
This systematic review and meta-analysis has several
limitations that are worthy of comment. First, the lack of trials
available for the effect modification analysis and differences in
the treatment regimens and outcomes reported in the trials
meant that we could not conduct a meta-analysis of effect
modification analyses. However, the largest trial provided no
evidence for effect modification. Second, we used aggregate
rather than participant data, which meant we were limited in the
precision with which we could conduct subgroup analyses and
our ability to homogenize the genotype comparisons or
outcomes reported. In an attempt to address this, we used a
genetic analysis model (any reduced function CYP2D6 allele
versus none) that aimed to simplify the genetic comparison,
which allowed us to include all studies in the analysis. Although
the outcomes reported did differ considerably between studies,
our approach was to generate composite outcomes to pool the
individual outcomes reported across studies to maximize
Figure 3.  Subgroup analyses of the association between any reduced function CYP2D6 allele vs. none for the composite
outcome of all-cause mortality and surrogate endpoints for overall survival (including non-fatal events).  
doi: 10.1371/journal.pone.0076648.g003
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power. Because use of composites may obscure associations
with individual constituents, we also investigated the
association of CYP2D6 genotype with individual outcomes.
Our systematic review is timely and an important addition to
recent findings from two large clinical trials [20,22] that both
failed to show evidence of a CYP2D6 genotype by tamoxifen
interaction, and the subsequent debate that ensued [9,35,36].
Furthermore, this systematic review and meta-analysis is likely
to add to the on-going debate on the potential use of surrogate
markers for studies of breast cancer outcomes. In the absence
of a validated surrogate marker for overall survival (the gold-
standard outcome, for which we did not identify an association
of CYP2D6 genotype on either the composite all-cause
mortality or individual outcome analyses), the associations
between CYP2D6 genotype and surrogate endpoints for overall
survival that we identified should be interpreted with caution.
Conclusions
Despite a weak association between CYP2D6 genotype and
surrogate endpoints for overall survival, we did not identify an
association between CYP2D6 genotype and tamoxifen
response for all-cause mortality or overall survival. The current
evidence does not support the use of CYP2D6 genotyping to
guide tamoxifen prescribing for the treatment of breast cancer.
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